bioRxivBiophysicsPreprint
PAM-DB: Revealing Protein Activation Mechanisms for Next-Generation Rational Drug Discovery
Xiaohong Zhu, Xiangyu Li, Yaning Hou, Ruifeng ZhouiD, Yingchao Yan, Arieh WarsheliD, Chen BaiiD
- Citations
- 0
Abstract
Current rational drug design relies predominantly on computational (CADD/AIDD) methods that model binding thermodynamics and static conformations of target proteins, primarily in their inactive states. However, the kinetic parameters that govern experimental efficacy-such as catalytic turnover and signaling potency-are determined by molecular interactions with transition states (TS), intermediate states (IS), and the entire continuum of conformations along the least free-energy activation pathway. The absence of this dynamic dimension has fundamentally limited the predictive power and success rate of conventional structure-based approaches. Here, we present a structural database that systematically maps the complete activation trajectories of pharmaceutically relevant targets, encompassing TS, IS, and all connecting conformational ensembles. This resource offers multiple strategic advantages for drug discovery: enabling rational targeting of previously "undruggable" proteins, facilitating biased agonism/antagonism design, revealing cryptic allosteric sites in inactive conformations, identifying novel transient pockets along the activation route, rationalizing the mechanisms of existing drugs, predicting mutational effects on activation barriers, and prospectively forecasting drug resistance and off-target liabilities. We demonstrate the utility of this database through representative case studies and provide implementation guidelines for integration into existing discovery pipelines. More detailed information can be found at our website: https://www.momedpamdb.com/en.
- assay: protein structure
- research focus: drug response / drug discovery
- research focus: protein folding & dynamics
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pharmacophore-guided de novo drug design with diffusion bridge
Conghao Wang, Jagath Chandana Rajapakse·bioRxiv·Dec 18, 2024
- Kincore: a web resource for structural classification of protein kinases and their inhibitors
Vivek Modi, Roland L. Dunbrack·Nucleic Acids ResearchPeer-reviewed·Sep 30, 2021
- Identifying Novel Targets by using Drug-binding Site Signature: A Case Study of Kinase Inhibitors
Hammad Naveed, Corinna Reglin, … Michael L. Maitland·bioRxiv·Dec 1, 2019
- An expanded view of ligandability in the allosteric enzyme PTP1B from computational reanalysis of large-scale crystallographic data
T. Mehlman, H. M. Ginn, D. A. Keedy·bioRxiv·Jan 5, 2024
- Identification of putative druggable pockets in PRL3, a significant oncology target, using in silico analysis
G. M. Bennett, J. Starczewski, M. V. C. dela Cerna·bioRxiv·Jul 31, 2023
- DiPPI: A curated dataset for drug-like molecules in protein-protein interfaces
Fatma Cankara, Simge Senyuz, … Özlem Keskin·Journal of Chemical Information and ModelingPeer-reviewed·Jun 22, 2024